Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

Abstract

Conclusions: the achieved results point to the specific therapeutical response to different groups of antidepressive drugs in adolescence, which may be explained by psychobiological and age factors, and especially to the incomplete morphofunctional brain maturation, and with the hormone and immunological disbalance in puberty. This confirms the necessity to single out adolescent psychopharmacotherapy into a special area and to study it on different levels. Duloxetine resulted in a significant reduction in severity of overall pain compared with placebo. Duloxetine was well tolerated and none of the duloxetine-treated patients reported any serious adverse events. These results indicate that duloxetine administered at 60 mg once daily is a safe and efficacious treatment of MDD. Moreover, these results also indicate that duloxetine may be an important treatment for MDD patients with physical symptoms, including pain.

Duloxetine versus Routine Care in the Long-Term Management of Diabetic Peripheral Neuropathic Pain

“…33 In the earlier study, there were no adverse events that were reported significantly more frequently in duloxetine-treated patients compared with routine care-treated patients. The study reported here provides additional evidence that duloxetine is safe for long-term therapy of patients at least 18 years old diagnosed with DPNP, and the overall safety profile reported here appears to be similar to that observed in major depressive disorder patients [22][23][24][25]38 as well as in that observed in other double-blind placebocontrolled studies of duloxetine in patients with DPNP. 27,28 …”

“…The observed increase in pulse rate for the duloxetine-treated patients could be expected due to elevations in NE tone. 37 These results are supportive of earlier clinical trials with duloxetine [22][23][24][25][27][28][29] and suggest that duloxetine has a safe cardiovascular profile. Routine care-treated patients experienced significantly higher mean changes in QT, PR, and QRS intervals compared with duloxetine-treated patients.…”

“…Patients were seen after 1 week (week 14) of treatment with either duloxetine or routine care. They were then seen again at weeks 17,21,25,33,41,49,57, and 65 of treatment. Compliance was defined as taking between 80% and 120% of the study medication prescribed for each interval.…”

“…Duloxetine (40 to 120 mg daily) has been shown to be safe and effective in the treatment of major depression. [22][23][24][25][26] Duloxetine is the first Food and Drug Administration (FDA)-approved prescription drug for the management of DPNP. In a randomized, controlled, 12-week trial comparing duloxetine 60 mg once daily (QD) and duloxetine 60 mg twice daily (BID) or duloxetine 20 mg QD with placebo in 457 patients with DPNP and without depression, duloxetine was found to be effective and safe for DPNP management.…”

A eficácia do milnaciprano em pacientes ambulatoriais com transtorno depressivo maior não respondedores ao tratamento com ISRSs: um estudo aberto de 12 semanas

“…There are at least two reasons why a clinician thinks about using a dual action antidepressant after a SSRI failed. First, it is based on the idea that an antidepressant that has a larger spectrum of action (i.e., that simultaneously enhance both serotoninergic as well as noradrenergic systems) would be more effective than a "single" system action [9][10][11][12][13] . Second is that after a failure for an antidepressant it is generally recommended to change for a drug from another class with a different mechanism of action 14 .…”